Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Views On Emerging Markets: J.P. Morgan Healthcare Conference

This article was originally published in PharmAsia News

Executive Summary

During the world’s largest health care investor conference there was plenty of discussion on emerging markets, including three presentations that stood out to PharmAsia News: GSK on the China compliance crisis; Sanofi on slowing GDP growth; and Medtronic on business model innovation.

You may also be interested in...



Asia Spotlight: China Eclipses Japan To Become Second Largest Pharma Market

Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.

China Eclipses Japan To Become Second Largest Pharma Market

Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.

Samsung, Merck Look To Take On Sanofi’s Lantus With Latest Deal

In the latest win for Samsung Bioepis, the Korean company will help develop and manufacture a late-stage insulin glargine candidate with Merck.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel